Temporary Passive Shunt for Visceral Protection During Open Thoracoabdominal Aortic Repair Under Intraoperative Advanced Hemodynamic and Perfusion Monitoring: Tertiary Hospital Institutional Bundle and Preliminary Mid-Term Results.

Temporary Passive Shunt for Visceral Protection During Open Thoracoabdominal Aortic Repair Under Intraoperative Advanced Hemodynamic and Perfusion Monitoring: Tertiary Hospital Institutional Bundle and Preliminary Mid-Term Results.

Publication date: Aug 27, 2025

Background: The perfusion of viscera, kidney, and spinal cord represents one of the main concerns during open repair (OR) of Thoraco-Abdominal Aortic Aneurisms (TAAAs). Passive shunting (PS) has been historically used for intraoperative distal aortic perfusion but has been progressively replaced almost entirely by partial left-sided heart or total cardiopulmonary bypass with extra-corporeal circulation (ECC). Despite several advantages of these methods, PS still has potential in mitigating some drawbacks of long extracorporeal circuits connected with centrifugal or roller pumps, such as the need for cardiac and great vessels cannulation, priming and large intravascular fluid volume shifts, high heparin dose, immunosuppressive effects, and systemic inflammatory response syndrome. Methods: This study prospectively analyzed data of a cohort of patients who underwent TAAA OR using a PS in a single institution. Outcomes of interest were mortality, rate of mesenteric, renal and spinal cord ischemia, cardiac complications, and intraoperative hemodynamic stability achieved in this setting. Our institutional bundle and a comprehensive literature review about the different configurations and applicability of PS for TAAA OR is also reported. The search was performed based on three databases (PubMed, EMBASE, and Cochrane Library) by two independent reviewers (LS and AA) from inception to 31 December 2023, and the reported clinical results (visceral, renal, and spinal cord complications and mortality) using PS during TAAAs OR were analyzed. Results: Between March 2021 and December 2023, 51 TAAA repairs were performed and eleven patients (n = 8, 73% male; mean age 67 years, range 63-79) were operated using a PS for a total of one (9%) type I, one (9%) type II, two (18%) type III, five (45%) type IV, and two (18%) type V TAAA. In our early experience, PS was indicated for limited staff resources during the COVID-19 pandemic to treat five non-deferable cases. The sixth and seventh patients were selected for PS as they already had a functioning axillo-bifemoral bypass that was used for this purpose. For the most recent cases, PS was chosen as the primary perfusion method according to a score based on clinical and anatomical factors with ECC as a bailout strategy. Selective renal perfusion with cold (4 ^0C) Custodiol solution was the method of choice for renal protection in all cases while antegrade perfusion of the coeliac trunk and the superior mesenteric artery was assured by PS through a loop graft (8-10mm) proximally anastomosed to the axillary artery (10 patients, 90. 9%) or the descending thoracic aorta (one patient, 9%) and distally anastomosed to the infrarenal aorta (3), common iliac (3), or femoral vessels (5). In-hospital mortality was 9% as one patient died on the 10th postoperative day from mesenteric ischemia following hemodynamic instability; permanent spinal cord ischemia rate was 0% and the rate of AKI stage 3 was 9% (one patient). Bailout shifting to ECC was never required. No cardiac complications, nor a significant increase in serum CK-MB were reported in any patient. No prolonged severe intraoperative hypotension episodes (Mean Arterial Pressure

Open Access PDF

Concepts Keywords
10th complications
Hemodynamic end-organ ischemia
Kidney paraparesis
Library paraplegia
renal failure
TAAA
Thoraco-Abdominal Aneurysm Repair
visceral protection

Semantics

Type Source Name
drug DRUGBANK Heparin
disease MESH systemic inflammatory response syndrome
disease MESH spinal cord ischemia
disease MESH complications
drug DRUGBANK Etoperidone
disease MESH COVID-19 pandemic
disease MESH mesenteric ischemia
disease MESH hypotension
disease MESH bleeding
disease IDO role
disease MESH Emergency
drug DRUGBANK Coenzyme M
disease MESH syndrome
disease MESH Aneurysm
disease MESH renal failure
disease MESH paraplegia
disease MESH thoracoabdominal aortic aneurysms
disease MESH death
drug DRUGBANK Isoxaflutole
disease IDO intervention
disease IDO blood
disease MESH morbidity
disease IDO history
disease MESH cerebrospinal fluid drainage
disease MESH hypothermia
disease MESH ischemia
disease MESH infarction
disease MESH Acute renal failure
drug DRUGBANK Cysteamine
drug DRUGBANK Creatinine
drug DRUGBANK Acetylsalicylic acid
disease MESH frailty
disease MESH hypertension
drug DRUGBANK Oxygen
disease IDO cell
disease MESH Dissecting aneurysm
disease MESH atrial fibrillation
disease MESH Infection
disease MESH Cancer
disease MESH Contraindication
disease MESH thrombus
disease IDO algorithm
drug DRUGBANK Amifampridine
disease MESH stroke
drug DRUGBANK Sulodexide
disease MESH aortic aneurysm
drug DRUGBANK Norepinephrine
drug DRUGBANK Ephedrine

Original Article

(Visited 13 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *